Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
03/2010
03/24/2010EP1067962B1 Derivatives of pneumococcal choline binding proteins for vaccines
03/24/2010CN101680897A Predicting response to a her dimerisation inhibitor based on low her3 expression
03/24/2010CN101680036A raccoon poxvirus expressing rabies glycoproteins
03/24/2010CN101679966A Genetically recombinant antibody composition having enhanced effector activity
03/24/2010CN101679526A Humanized and chimeric anti-TROP-2 antibodies that mediate cancer cell cytotoxicity
03/24/2010CN101679523A Novel fully human anti-vap-1 monoclonal antibodies
03/24/2010CN101679522A Modulation of tumor microenvironment
03/24/2010CN101679521A Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind CD154 and uses thereof
03/24/2010CN101679519A Antibodies to CD200R
03/24/2010CN101679517A Novel antibody molecules and nucleic acids binding to fungal stress protein hsp90
03/24/2010CN101679516A Antigen-binding proteins targeting s. aureus ORF0657
03/24/2010CN101679515A Novel human anti-r7v antibodies and uses thereof
03/24/2010CN101679513A Recombinant antibodies for treatment of respiratory syncytial virus infections
03/24/2010CN101679512A Human antibodies against hepatitis c virus (hcv) uses thereof
03/24/2010CN101679508A Vaccines based on targeting antigen to dcir expressed an antigen-presenting cells
03/24/2010CN101679506A Compositions and methods for binding sphingosine-1-phosphate
03/24/2010CN101678104A New indications for anti- il-i-beta therapy
03/24/2010CN101678103A antibody formulation
03/24/2010CN101678102A Combined human il- 18 and anti cd20 antibody cancer treatment
03/24/2010CN101678101A Pharmaceutical compositions capable of inducing apoptosis in tumour cells, useful for diagnosis and treatment of B-chronic lymphocytic leukaemia
03/24/2010CN101678100A methods of treating systemic lupus erythematosus
03/24/2010CN101678099A Therapeutic compositions for boosting the effect of antibody therapy against the epidermal growth factor receptor
03/24/2010CN101678098A Class a oligonucleotides with immunostimulatory potency
03/24/2010CN101678097A Vaccination regimen for b-cell vaccines
03/24/2010CN101678096A oil-in-water emulsion influenza vaccine
03/24/2010CN101678095A Novel neutralizing immunogen (nimiv) of rhinovirus and its use for vaccine applications
03/24/2010CN101678094A formulation of meningitis vaccines
03/24/2010CN101678093A Vaccine for the prevention of breast cancer relapse
03/24/2010CN101678092A Nucleic acids
03/24/2010CN101678091A Lyophilised antigen composition
03/24/2010CN101678090A Compositions and methods for the prevention and treatment of autoimmune conditions
03/24/2010CN101678082A Methods for promoting protection and regeneration of bone marrow using CXCL9 and anti-CXCL9 antibodies
03/24/2010CN101678065A Vaccine therapy for choroidal neovascularization
03/24/2010CN101678012A An allergen dosage form comprising an antihistamine
03/24/2010CN101676389A Modified vaccinia ankara virus variant
03/24/2010CN101676388A Avian cell lines for the production of useful substances
03/24/2010CN101676301A Antibody for inhibitting growth of colorectal carcinoma and its use in preparation of medicament and kit
03/24/2010CN101676299A Peptides and/or proteins and use thereof for the production of a therapeutic and/or prophylactic medicament
03/24/2010CN101675994A Therapy vaccine preparation
03/24/2010CN101675993A melan-a peptide analogue-virus-like-particle conjugates
03/24/2010CN101675992A Beta-amyloid-analogue-t-cell epitop vaccine
03/24/2010CN101675922A Parakeratosis inhibitor, pore-shrinking agent and skin preparation for external use
03/24/2010CN100595211C Angiopoietin-2 specific binding agents
03/24/2010CN100594935C Antibodies that immunospecifically bind to trail receptors
03/24/2010CN100594934C Amended recombinant cells (ARCs) for the production and delivery of antiviral agents, adjuvants and vaccine accelerants
03/24/2010CN100594932C Tumor necrosis factor antagonists and their use in endometriosis
03/24/2010CN100594931C The pIFN-gamma gene adjuvant for pig vaccine and its prepn process
03/23/2010US7683159 Tenascin-W compositions and uses thereof
03/23/2010US7683061 rheumatoid arthritis, systemic lupus erythematosus (SLE), idiopathic (immune) thrombocytopenia (ITP), glomerulonephritis and vasculitis; reduced drug toxicity
03/23/2010US7683041 Microgel particles for the delivery of bioactive materials
03/23/2010US7683033 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
03/23/2010US7682796 detecting bacterial infection by a polyglutamic acid- (PGA-) producing pathogen ; administration of a capsular polypeptide of a pathogen of interest and a CD40 agonist; immunization
03/23/2010US7682627 Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier
03/23/2010US7682619 comprising hemaggluttinin gene; host cells
03/23/2010US7682618 Generation of virus-like particles and use as panfilovirus vaccine
03/23/2010US7682614 blocking or reducing airway hyperresponsiveness using beta -galactosylceramide or anti-CD1d antibody; systemic lupus erythematosus (SLE), cancer, atherosclerosis, and allergic disease
03/23/2010US7682613 Anti-leukocyte recruitment therapy for the treatment of seizures and epilepsy
03/23/2010US7682612 Chronic Lymphocytic Leukemia (CLL) is treated with antibodies directed against the CD20 antigen; rituximab; chemotherapy
03/23/2010US7682611 Chemokine receptor-4 (CXCR4) specific immunoglobulin for diagnosis, prevention and treatment of viral or bacterial infection
03/23/2010US7682610 Vascular endothelial growth factor receptor specific immunoglobulin for diagnosis, prevention and treatment of cell proliferative disorders
03/23/2010US7682609 lyophilized mixture of a recombinant humanized HER2 monoclonal antibody, a lyoprotectant, and a buffer; physical and chemical stability and integrity upon lyophilization and storage; breast cancer
03/23/2010US7682608 Stabilized preparations containing antibody
03/23/2010US7682607 Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
03/23/2010CA2424656C Composition and method for stable injectable liquids
03/23/2010CA2356737C Tumor necrosis factor antagonists and their use in endometriosis
03/23/2010CA2353523C Allo and auto-reactive t-cell epitopes
03/23/2010CA2329000C Stabilised virus preparation
03/23/2010CA2309639C Small peptides and methods for treatment of asthma and inflammation
03/23/2010CA2225388C Low pathogenicity prrs live virus vaccines and methods of preparation thereof
03/23/2010CA2223412C Method for prolonging the expression of a gene of interest using soluble ctla4 molecules
03/23/2010CA2209124C Antitumor agent effect enhancer containing il-6 antagonist
03/23/2010CA2194797C Nucleic acid containing composition, preparation and uses of same
03/23/2010CA2194448C Method of priming an immune response in a one-day old animal
03/23/2010CA2149818C Combination of necrosis-inducing substances with substances which are activated by necroses for the selective therapy of tumors and inflammatory disorders
03/18/2010WO2010030979A2 Targeting pathogenic monocytes
03/18/2010WO2010030840A2 Novel receptor and uses thereof
03/18/2010WO2010030813A2 Methods for inhibiting ocular angiogenesis
03/18/2010WO2010030789A1 Device and method for inhibiting complement activation
03/18/2010WO2010030653A2 Nurr1 interacting protein (nuip)
03/18/2010WO2010030182A2 Antigen-binding proteins that inhibit superantigens for the treatment of skin diseases
03/18/2010WO2010029497A1 Treatment of endometriosis
03/18/2010WO2010029435A1 Pd-1 specific antibodies and uses thereof
03/18/2010WO2010029434A1 Pd-1 specific antibodies and uses thereof
03/18/2010WO2010029293A1 Non-typhoidal salmonella vaccines
03/18/2010WO2010029260A1 Synthetic gene construct encoding an hiv-1 gag and the use thereof for obtaining anti-hiv-1 vaccines
03/18/2010WO2010028859A1 Factor h binding protein immunogens
03/18/2010WO2010028798A1 Multivalent antibodies
03/18/2010WO2010028797A1 Multivalent antibodies
03/18/2010WO2010028795A1 Multivalent antibodies
03/18/2010WO2010010549A3 Methods of altering peripheral b cell populations and uses thereof
03/18/2010WO2010010469A3 Amyloid beta (x - 38.. 43) oligomers, and processes, compositions, and uses thereof
03/18/2010WO2010009368A3 Compositions for the detection and treatment of colorectal cancer
03/18/2010WO2010006144A3 Influenza hemagglutinin and neuraminidase variants
03/18/2010WO2009154697A3 Disc-1 pathway activators in the control of neurogenesis
03/18/2010WO2009142738A3 Compositions and methods for diagnosing and treating cancer
03/18/2010WO2009140649A8 Rab3b for the treatment and prevention of parkinson's disease
03/18/2010WO2009138752A3 Fish vaccine
03/18/2010WO2009137758A3 Igf-ii/gf-iie binding proteins
03/18/2010WO2009132209A3 Methods and compounds for mitigating pathogenic outbreaks using replikin count cycles
03/18/2010WO2009121065A3 Modulation and repletion/enhancement of the complement system for treatment of trauma
1 ... 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 ... 1823